HHS In role
Steven Kozlowski
Chief Scientist, FDA
The FDA's chief scientist, a career agency scientist who first took the role in an acting capacity in October 2024 and also directed a pharmaceutical-quality assessment office in CDER. Kozlowski sets the agency's regulatory-science priorities — and made news in October 2026 by putting aging and longevity into the FDA's official focus areas for the first time.
Role status — October 2026: Kozlowski is the FDA’s chief scientist, the head of the Office of the Chief Scientist and the agency’s senior voice on regulatory science. He first took the role in an acting capacity in October 2024, and 2026 agency appearances and coverage style him chief scientist outright. Alongside the chief scientist post, he has served as a director in CDER’s Office of Pharmaceutical Quality — a working regulatory-science job inside the drug center.
Kozlowski is a career FDA scientist rather than a political arrival, and his file is the agency’s research agenda itself: the Focus Areas of Regulatory Science (FARS), the document that tells FDA staff, funders, and industry where the agency’s science is heading. His signature move so far came at the ARDD 2026 aging-research conference in Boston in early October 2026, where he announced that aging and longevity will be included in the updated FARS, planned for early fiscal 2027 — the first time the agency’s regulatory-science priorities have formally taken up aging as a topic.
At ARDD he paired the announcement with the hard problem: aging has no agreed, qualified endpoint a trial can be run against, and he argued for a shared, pre-competitive endpoint with regulatory acceptance behind it so feasible trials can be designed. Trade coverage of the appearance was careful to note the limit — FARS is a signal to the field, not a change in review requirements, and no one at FDA would describe an aging approval pathway until developers bring evidence. He also carries the chief scientist’s public-facing duties, including the April 2026 Grollman Lecture on regulatory science and medical product development at the University of Maryland School of Pharmacy.
Why tracked here: Kozlowski decides what counts as the FDA’s scientific frontier — and putting longevity on that list is the kind of quiet agenda-setting that shapes what the agency is prepared to approve years from now.
Sources (Oct 2026): Genetic Engineering & Biotechnology News, Oct. 2026; Citeline In Vivo, Oct. 21, 2026; RAPS (acting appointment and CDER role); University of Maryland Elm, Mar. 2026.